2010-7

Medtronic Enters into Licensing Agreement with AGA Medical Holdings: A Move to Benefit from Huge Market Opportunity in Structural Heart Defects and Vascular Abnormalities

Summary

GlobalData’s report, “Medtronic Enters into Licensing Agreement with AGA Medical Holdings: A Move to Benefit from Huge Market Opportunity in Structural Heart Defects and Vascular Abnormalities” provides key information and analysis on the Medtronic’s licensing agreement with AGA Medical Holdings. The report provides information on deal rationale, AGA Medical Holdings pipeline products and the clinical trials the company is conducting.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- The report provides qualitative information on rationale behind Medtronic’s licensing agreement with AGA Medical Holdings
- Market opportunity in the treatment of structural heart defects and vascular abnormalities
- Qualitative analysis on licensing agreement between Medtronic and AGA Medical Holdings

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the cardiovascular devices market
- Understand the key technologies that are expected to drive the cardiovascular devices market in the future
- Exploit M&A opportunities by identifying key areas of growth
- Make more informed business decisions from the insightful and in-depth analysis of the global structural heart defects and vascular abnormalities market

目录

1 Table of Contents
1 Table of Contents 1
1.1 List of Tables 1
1.2 List of Figures 1
2 Medtronic Enters into Licensing Agreement with AGA Medical Holdings: A Move to Benefit from Huge Market Opportunity in Structural Heart Defects and Vascular Abnormalities 1
2.1 Deal Summary 1
2.2 Deal Rationale 1
2.2.1 Medtronic is Expected to Receive Royalty Income from AGA Medical’s Amplatzer Sales 1
2.2.2 Huge Market Opportunity in Treatment of Structural Heart Defects and Vascular Abnormalities 2
2.2.3 Medtronic to Receive Settlement Payment for Jervis Patents Infringement by AGA Medical 3
2.3 Company Profiles 3
3 Appendix 4
3.1 Research Methodology 4
3.2 Secondary Research 4
3.3 Primary Research 5
3.4 Models 5
3.5 Forecasts 5
3.6 Expert Panels 5
3.7 GlobalData Consulting 5
3.8 Contact Us 5
3.9 Disclaimer 6

1.1 List of Tables
Table 1: AGA Medical, Clinical Trials 2
Table 2: AGA Medical, Pipeline Products 2
Table 3: Medtronic, Company Profile 3
Table 4: AGA Medical Holdings, Company Profile 3

1.2 List of Figures
Figure 1: AGA Medical, Treatable Disease Conditions 2
Figure 2: GlobalData Methodology 4